What a Dutch population study of MammaPrint and Oncotype DX reveals about access, adoption and chemotherapy decisions A short evidence blog from Odelle Technology 9% → 25% → 37% Use …

How innovators can enter RIGA, build a credible regional proposition,and move from product evidence to system-level adoption The next market-access question is not simply whether a technology can be reimbursed. …

What to partner with, when to approach pharmaceutical companies and how to turn an app into a strategic treatment asset A medicine does not create value when it leaves the …

Why early HTA, health-economic modelling and payer dialogue should begin before the pivotal trial is finalised A medical device, diagnostic or digital-health technology can be safe, technically successful and supported …

An evidence-informed guide to patient-pathway value, reimbursement, strategic fit and acquisition readiness Most healthcare-app founders believe they are building a product. A future buyer may be looking for something entirely …

Germany gives pharmaceutical companies unusually rapid access to a major European market. A newly authorised medicine can generally enter reimbursed use while its comparative benefit and long-term reimbursement amount are …